Detalles de la búsqueda
1.
Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Hum Vaccin Immunother;
19(3): 2285089, 2023 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38111106
Resultados
1 -
1
de 1
1
Próxima >
>>